Compare JBI & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBI | JANX |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.0M | 847.1M |
| IPO Year | 2021 | 2021 |
| Metric | JBI | JANX |
|---|---|---|
| Price | $5.18 | $14.50 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 13 |
| Target Price | $9.17 | ★ $47.00 |
| AVG Volume (30 Days) | ★ 1.7M | 865.2K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | $9.36 | N/A |
| Revenue Next Year | $3.16 | N/A |
| P/E Ratio | $12.96 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.26 | $12.12 |
| 52 Week High | $10.80 | $35.34 |
| Indicator | JBI | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 50.48 | 51.12 |
| Support Level | $5.17 | $13.10 |
| Resistance Level | $5.66 | $14.57 |
| Average True Range (ATR) | 0.27 | 0.57 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 76.57 | 73.97 |
Janus International Group Inc is a manufacturer and supplier of turnkey solutions for self-storage, commercial, and industrial building Solutions. The company provides products that include roll-up and swing doors, hallway systems, relocatable storage MASS (Moveable Additional Storage Structures) units, and technologies for automating facility and door operation. It is operated through two geographic regions; Janus North America and Janus International. The Janus International segment is comprised of a subsidiary whose production and sales are largely in Europe and Australia. The Janus North America segment is comprised of all the other entities.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.